(Q51818625)

English

Prospective study of methotrexate treatment for rheumatoid arthritis treated legitimately according to the government recommended 8 mg/week dose.

scientific article published on 22 July 2009

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

13 April 2018

http://europepmc.org/abstract/MED/19626390

Prospective study of methotrexate treatment for rheumatoid arthritis treated legitimately according to the government recommended 8 mg/week dose. (English)

1 reference

Europe PubMed Central

13 April 2018

http://europepmc.org/abstract/MED/19626390

rheumatoid arthritis

1 reference

based on heuristic

inferred from title

1 reference

based on heuristic

inferred from title

author name string

Akira Hashiramoto

1

1 reference

Europe PubMed Central

13 April 2018

http://europepmc.org/abstract/MED/19626390

Kazuko Shiozawa

2

1 reference

Europe PubMed Central

13 April 2018

http://europepmc.org/abstract/MED/19626390

Yasushi Tanaka

3

1 reference

Europe PubMed Central

13 April 2018

http://europepmc.org/abstract/MED/19626390

Takashi Yamane

4

1 reference

Europe PubMed Central

13 April 2018

http://europepmc.org/abstract/MED/19626390

Miki Murata

5

1 reference

Europe PubMed Central

13 April 2018

http://europepmc.org/abstract/MED/19626390

Chihiro Tanaka

6

1 reference

Europe PubMed Central

13 April 2018

http://europepmc.org/abstract/MED/19626390

Yasuhiro Terashima

7

1 reference

Europe PubMed Central

13 April 2018

http://europepmc.org/abstract/MED/19626390

Kozo Koyama

8

1 reference

Europe PubMed Central

13 April 2018

http://europepmc.org/abstract/MED/19626390

Natsuko Nakagawa

9

1 reference

Europe PubMed Central

13 April 2018

http://europepmc.org/abstract/MED/19626390

Shuji Abe

10

1 reference

Europe PubMed Central

13 April 2018

http://europepmc.org/abstract/MED/19626390

Rhosuke Yoshihara

11

1 reference

Europe PubMed Central

13 April 2018

http://europepmc.org/abstract/MED/19626390

Yasuhiro Saegusa

12

1 reference

Europe PubMed Central

13 April 2018

http://europepmc.org/abstract/MED/19626390

Ken Tsumiyama

13

1 reference

Europe PubMed Central

13 April 2018

http://europepmc.org/abstract/MED/19626390

Koichiro Komai

14

1 reference

Europe PubMed Central

13 April 2018

http://europepmc.org/abstract/MED/19626390

Yoshitada Sakai

15

1 reference

Europe PubMed Central

13 April 2018

http://europepmc.org/abstract/MED/19626390

Shunichi Shiozawa

16

1 reference

Europe PubMed Central

13 April 2018

http://europepmc.org/abstract/MED/19626390

publication date

22 July 2009

1 reference

Europe PubMed Central

13 April 2018

http://europepmc.org/abstract/MED/19626390

Modern Rheumatology

1 reference

Europe PubMed Central

13 April 2018

http://europepmc.org/abstract/MED/19626390

19

1 reference

Europe PubMed Central

13 April 2018

http://europepmc.org/abstract/MED/19626390

6

1 reference

Europe PubMed Central

13 April 2018

http://europepmc.org/abstract/MED/19626390

637-642

1 reference

Europe PubMed Central

13 April 2018

http://europepmc.org/abstract/MED/19626390

New drugs for rheumatoid arthritis

1 reference

https://api.crossref.org/works/10.3109%2FS10165-009-0205-X

21 January 2018

Rational use of new and existing disease-modifying agents in rheumatoid arthritis

1 reference

https://api.crossref.org/works/10.3109%2FS10165-009-0205-X

21 January 2018

Methotrexate therapy in rheumatoid arthritis: 15 years experience.

1 reference

https://api.crossref.org/works/10.3109%2FS10165-009-0205-X

21 January 2018

The american rheumatism association 1987 revised criteria for the classification of rheumatoid arthritis

1 reference

https://api.crossref.org/works/10.3109%2FS10165-009-0205-X

21 January 2018

Missing data in randomized controlled trials of rheumatoid arthritis with radiographic outcomes: a simulation study

1 reference

https://api.crossref.org/works/10.3109%2FS10165-009-0205-X

21 January 2018

Disease remission and sustained halting of radiographic progression with combination etanercept and methotrexate in patients with rheumatoid arthritis

1 reference

https://api.crossref.org/works/10.3109%2FS10165-009-0205-X

21 January 2018

Dose escalation of parenteral methotrexate in active rheumatoid arthritis that has been unresponsive to conventional doses of methotrexate: a randomized, controlled trial

1 reference

https://api.crossref.org/works/10.3109%2FS10165-009-0205-X

21 January 2018

Methotrexate in rheumatoid arthritis: an update with focus on mechanisms involved in toxicity

1 reference

https://api.crossref.org/works/10.3109%2FS10165-009-0205-X

21 January 2018

Proposals for leflunomide use to avoid lung injury in patients with rheumatoid arthritis

1 reference

https://api.crossref.org/works/10.3109%2FS10165-009-0205-X

21 January 2018

Quality-of-life assessment in rheumatoid arthritis

1 reference

https://api.crossref.org/works/10.3109%2FS10165-009-0205-X

21 January 2018

Identifiers

10.3109/S10165-009-0205-X

1 reference

Europe PubMed Central

13 April 2018

http://europepmc.org/abstract/MED/19626390

release_abaldfbdmjglvdcvgxvyu4tosm

1 reference

https://api.fatcat.wiki/v0/release/abaldfbdmjglvdcvgxvyu4tosm

24 November 2022

based on heuristic

mapped directly with Wikidata item

1 reference

Europe PubMed Central

13 April 2018

http://europepmc.org/abstract/MED/19626390

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q51818625&oldid=1836113716"